论文标题:糖肾化瘀煎对早期糖尿病肾病大鼠非酶糖基化影响的实验研究
The Experimental Research of the Influence of ～(59)Fe"s Metabolism and Fe Transferrin Receptor-mRNA Expressed to the Rat of Deficient Spleen Syndrome by Replenishing Spleen Method
论文作者 刘琼
论文导师 成肇智,论文学位 硕士,论文专业 中医诊断学
论文单位 湖北中医学院,点击次数 59,论文页数 27页File Size1447k
2004-04-01论文网 http://www.lw23.com/lunwen_531649897/ 糖尿病肾病/中医药疗法;糖尿病肾病/非酶糖基化;糖基化终末产物;@糖肾化瘀煎
Diabetic nelhropathy/The therapy of traditional Chinese;medicine and medication;Diabetic nethropathy/ nonenzymatie glycosylation;Advanced glycation end-products;@ TangShenHuaYuJian
目的 通过观察糖肾化瘀煎对长期高血糖所致的早期粮尿病肾病大鼠(腹腔注射链脲佐菌素后诱导所形成)肾重、肾重指数(肾重／体重)、血糖、血尿素氮(BUN)、肌酐(Scr)、血糖基化终末产物AGEs、肾组织糖基化终末产物AGEs等指标的影响，从非酶糖基化角度探讨此制剂对糖尿病肾病早期的作用机理，并为糖肾化瘀煎的临床运用和进一步开发提供实验依据。 方法 60只Wistar大鼠，随机分为正常对照组(简称正常组)、模型组、糖肾化瘀煎大剂量组(简称大剂量组)、糖肾化瘀煎中剂量组(简称中剂量组)、糖肾化瘀小剂量组(简称小剂量组)五组。一次性空腹腹腔注射链脲佐菌素诱导糖尿病模型成功后，各治疗组即开始分别给予大、中、小剂量的糖肾化瘀煎水煎剂灌胃治疗6周，同时正常组和模型组分别给予等剂量的生理盐水灌胃6周。以上各组每日灌胃一次。6周后处死各组大鼠，收集标本，检测肾重、肾重指数、血糖、血尿素氮、肌酐、血糖基化终末产物、肾组织糖基化终末产物，所有实验数据均用SPSS软件包进行统计学处理。 结果 1 肾重、肾重指数 ①肾重：与正常组比较，模型组和大、小剂量组肾重显著增加(P＜0.01)，中剂量组无显著性变化(P＞0.05)。②肾重指数：与正常组比较，模型组和各治疗组显著增加(P＜0.05或P＜0.01)；与模型组比较，各治疗组显著性下降(P＜0.05或P＜0.01)。 2 血糖 治疗前、后模型组和各治疗组血糖与正常组比较均显著升高(P＜0.01)；6周后，各治疗组血糖与模型组比较显著下降(P＜0.05或P＜0.01)；自身前后比较，模型组有显著性升高(P＜0.05)，中、大剂量组有非常显著性下降(P＜0.01)，小剂量组变化不显著。 3 尿素氮(BUN)、肌酐(Scr) ①BUN：正常组、模型组及各治疗组无显著性差异(P＞0.05)。②Scr：与模型组比较，各治疗组显著下降(P＜0.05或P＜0.01)。 4 血清AGEs、肾组织AGEs曝光时间 ①血清AGEs：与正常组比较，模型组和各治疗组显著增加(P＜0.01)；与模型组比较、各治疗组显著下降(P＜0.05或P＜0.01)。②肾组织AGEs曝光时间：与正常组比较，模型组和各治疗组曝光时间显著缩短(P＜0.01)；与模型组比较，各治疗组曝光时间显著延长(P＜0.01)。 结论 糖肾化瘀煎对糖尿病肾脏病变能起到保护作用。其机制可能是通过降低血糖、降低血清糖基化终末产物和肾组织糖基化终末产物，从阻止和抑制非酶糖基化方面来防止早期肾脏病变，降低肾重指数，降低血肌酐改善肾功能。值得进一步研究和开发。
ObjectiveThrough observing the ei"fect of the TCM decoction TangShenHuaYuJian(TSHYJ) on the kidney weight, index of kidney hypertrophy(kidney weight/body weight), blood glucose , blood urea nitrogen(BUN), creatinine(Cr), blood advanced glycation end-products(AGEs), advanced glycation end-products(AGEs) in kidney tissue in the earlier stage of diabetic nephropalhy rats induced by injecting 3 -cytotoxins into abdomen, to explore the relationship between nonenzymatic glycosylation and diabetic nephropathy, and provide an experimental basis for clinical application and for further studying TSHYJ.MethodsThe sixty studied Wistar rats were randomly divided into five groups: normal control group(normal group), model group, high dose of TSHYJ group(high dose group), moderate dose of TSHYJ group(moderate dose group), low dose of TSHYJ group(low dose group). After inducing diabetic models by injecting (3 -cytotoxins into their abdomen successfully, the docoction of TSHYJ was given to the three treated groups and the same dose of saline was given to the normal group and the model group by stomach rearing once per day for six weeks. At the end of six weeks, all of the rats were killed and the kidney weight, index of kidney hypertrophy (kidney weight/body weight), blood glucose, blood urea nitrogen(BUN), creatinine (Cr), blood advanced glycation end-products(AGEs), advanced glycation end-products(AGEs) in kidney tissue of the rats of each group were tested. The results were analyzed with SPSS.Results1 Kidney weight and index of kidney hypertrophy (1) Kidney weight: the kidney weight of model high and low dose groups was distinctly heavier than that of normal group, P<0.01; moderate dose group had no change, P>0.05. (2)Index of kidney hypertrophy: the index of kidney hypertrophy of the three treated and model groups was distinctly higher, P< 0.05 or P <0.01 ; TSHYJ could markedly decrease the index of kidney hypertrophy , compared with the model group, P< 0.05 or P <0.01.2 Blood glucose The blood glucose of the treated and the model groups at pretreatment and post-treatment distinctly increased , compared with the normal group, P <0.01; After treatment, the blood glucose of the treated groups distinctly decreased , compared with the model group P< 0.05 or P <0.01 ; Compared pretreatment with post-treatment, the blood glucose of the model group distinctly increased , P <0.05, the moderate and high dose groups distinctly decreased , P <0.01 , the low dose group had no markedly change.3 BUN and Cr in serum (1)BUN: there were no distinct differences (P > 0.05)among the treated, the mode! and the normal groups. (2)Cr: the serum Cr of thetreated groups distinctly decreased, compared with the model group, P< 0.05 or P <0.01.4 AGEs in serum and AGEs fluorcscene exposure time in kidney tissue (1)AGEs in serum: AGEs in serum of the treated and the model groups distinctly increased , compared with the normal group, P <0.01; AGEs in serum of the treated groups distinctly decreased , compared with the model group, P< 0.05 or P <0.01 ; (2)AGEs fluorescene exposure time in kidney tissue: the exposure time of the treated and the model groups was distinctly shorten, compared with the normal group P <0.01; Compared with the model group, the exposure time of the treated groups was distinctly prolonged, P <0.01.ConclutionTSHYJ has certain renal protective, probably through lowering blood glucose, AGEs in serum and AGEs in kidney tissue, preventing early diabetic nethropathy by hindering and inhibiting nonenzymatie glycosylation . Decreasing the index of kidney hypertrophy and Cr in serum to improve renal function. So TSHYJ is worth further researching and developing.
|
